Evaluating the Potential of Chelation Therapy to Prevent and Treat Gadolinium Deposition from MRI Contrast Agents

Overview

Journal Sci Rep

Specialty Science

Date 2018 Mar 15

PMID 29535330

Citations 18

Authors

Julian A Rees

Gauthier J-P Deblonde

Dahlia D An

Camille Ansoborlo

Stacey S Gauny

Rebecca J Abergel

Affiliations

Soon will be listed here.

Abstract

Several MRI contrast agent clinical formulations are now known to leave deposits of the heavy metal gadolinium in the brain, bones, and other organs of patients. This persistent biological accumulation of gadolinium has been recently recognized as a deleterious outcome in patients administered Gd-based contrast agents (GBCAs) for MRI, prompting the European Medicines Agency to recommend discontinuing the use of over half of the GBCAs currently approved for clinical applications. To address this problem, we find that the orally-available metal decorporation agent 3,4,3-LI(1,2-HOPO) demonstrates superior efficacy at chelating and removing Gd from the body compared to diethylenetriaminepentaacetic acid, a ligand commonly used in the United States in the GBCA Gadopentetate (Magnevist). Using the radiotracer Gd to obtain precise biodistribution data, the results herein, supported by speciation simulations, suggest that the prophylactic or post-hoc therapeutic use of 3,4,3-LI(1,2-HOPO) may provide a means to mitigate Gd retention in patients requiring contrast-enhanced MRI.

Citing Articles

Temporal Assessment of Gadolinium Deposition and T1 Signal Intensity Changes in Rat Kidney with Single and Multiple Doses of Injection: An Experimental Study.

Alper F, Karaman A, Yalcin A, Sirinoglu B, Dincer B, Atila A Eurasian J Med. 2024; 56(1):47-51.

PMID: 39128076 PMC: 11059422. DOI: 10.5152/eurasianjmed.2024.23155.

Investigation of the effect of vitamin K1 prophylaxis on newborn screenings tests in newborns.

Caglayan M, Gonel A, Tayman C, Cakir U, Koyuncu I, Temiz E J Med Biochem. 2023; 42(3):376-382.

PMID: 37814616 PMC: 10560507. DOI: 10.5937/jomb0-40162.

Developing scandium and yttrium coordination chemistry to advance theranostic radiopharmaceuticals.

Carter K, Deblonde G, Lohrey T, Bailey T, An D, Shield K Commun Chem. 2023; 3(1):61.

PMID: 36703424 PMC: 9814396. DOI: 10.1038/s42004-020-0307-0.

High-throughput screening for discovery of benchtop separations systems for selected rare earth elements.

Nelson J, Cheisson T, Rugh H, Gau M, Carroll P, Schelter E Commun Chem. 2023; 3(1):7.

PMID: 36703327 PMC: 9814905. DOI: 10.1038/s42004-019-0253-x.

Nanoparticle-Mediated Radiotherapy Remodels the Tumor Microenvironment to Enhance Antitumor Efficacy.

Zhen W, Weichselbaum R, Lin W Adv Mater. 2022; 35(21):e2206370.

PMID: 36524978 PMC: 10213153. DOI: 10.1002/adma.202206370.

References

DURBIN P, Kullgren B, Xu J, Raymond K . Multidentate hydroxypyridinonate ligands for Pu(IV) chelation in vivo: comparative efficacy and toxicity in mouse of ligands containing 1,2-HOPO or Me-3,2-HOPO. Int J Radiat Biol. 2000; 76(2):199-214. DOI: 10.1080/095530000138853. View

Deblonde G, Sturzbecher-Hoehne M, Mason A, Abergel R . Receptor recognition of transferrin bound to lanthanides and actinides: a discriminating step in cellular acquisition of f-block metals. Metallomics. 2013; 5(6):619-26. PMC: 3672314. DOI: 10.1039/c3mt20237b. View

Abergel R, DAleo A, Leung C, Shuh D, Raymond K . Using the antenna effect as a spectroscopic tool: photophysics and solution thermodynamics of the model luminescent hydroxypyridonate complex [Eu(III)(3,4,3-LI(1,2-HOPO))]-. Inorg Chem. 2009; 48(23):10868-70. PMC: 2873866. DOI: 10.1021/ic9013703. View

Frenzel T, Lengsfeld P, Schirmer H, Hutter J, Weinmann H . Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol. 2008; 43(12):817-28. DOI: 10.1097/RLI.0b013e3181852171. View

Radbruch A, Weberling L, Kieslich P, Eidel O, Burth S, Kickingereder P . Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology. 2015; 275(3):783-91. DOI: 10.1148/radiol.2015150337. View

Abergel R, Durbin P, Kullgren B, Ebbe S, Xu J, Chang P . Biomimetic actinide chelators: an update on the preclinical development of the orally active hydroxypyridonate decorporation agents 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO). Health Phys. 2010; 99(3):401-7. PMC: 2921233. DOI: 10.1097/HP.0b013e3181c21273. View

Kanal E . Gadolinium based contrast agents (GBCA): Safety overview after 3 decades of clinical experience. Magn Reson Imaging. 2016; 34(10):1341-1345. DOI: 10.1016/j.mri.2016.08.017. View

Sherry A, Caravan P, Lenkinski R . Primer on gadolinium chemistry. J Magn Reson Imaging. 2009; 30(6):1240-8. PMC: 2853020. DOI: 10.1002/jmri.21966. View

Durbin P . Lauriston S. Taylor Lecture: the quest for therapeutic actinide chelators. Health Phys. 2008; 95(5):465-92. DOI: 10.1097/01.HP.0000326345.41816.c2. View

10.

Prybylski J, Maxwell E, Coste Sanchez C, Jay M . Gadolinium deposition in the brain: Lessons learned from other metals known to cross the blood-brain barrier. Magn Reson Imaging. 2016; 34(10):1366-1372. DOI: 10.1016/j.mri.2016.08.018. View

11.

Marckmann P, Skov L, Rossen K, Dupont A, Damholt M, Heaf J . Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006; 17(9):2359-62. DOI: 10.1681/ASN.2006060601. View

12.

Lancelot E . Revisiting the Pharmacokinetic Profiles of Gadolinium-Based Contrast Agents: Differences in Long-Term Biodistribution and Excretion. Invest Radiol. 2016; 51(11):691-700. DOI: 10.1097/RLI.0000000000000280. View

13.

An D, Kullgren B, Jarvis E, Abergel R . From early prophylaxis to delayed treatment: Establishing the plutonium decorporation activity window of hydroxypyridinonate chelating agents. Chem Biol Interact. 2016; 267:80-88. PMC: 5045775. DOI: 10.1016/j.cbi.2016.03.034. View

14.

Sturzbecher-Hoehne M, Leung C, DAleo A, Kullgren B, Prigent A, Shuh D . 3,4,3-LI(1,2-HOPO): in vitro formation of highly stable lanthanide complexes translates into efficacious in vivo europium decorporation. Dalton Trans. 2011; 40(33):8340-6. DOI: 10.1039/c1dt10840a. View

15.

Rogosnitzky M, Branch S . Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. Biometals. 2016; 29(3):365-76. PMC: 4879157. DOI: 10.1007/s10534-016-9931-7. View

16.

DURBIN P, JEUNG N, Kullgren B, Clemons G . Gross composition and plasma and extracellular water volumes of tissues of a reference mouse. Health Phys. 1992; 63(4):427-42. DOI: 10.1097/00004032-199210000-00007. View

17.

Choi T, Endsley A, Bunin D, Colas C, An D, Morales-Rivera J . Biodistribution of the multidentate hydroxypyridinonate ligand [(14) C]-3,4,3-LI(1,2-HOPO), a potent actinide decorporation agent. Drug Dev Res. 2015; 76(3):107-22. DOI: 10.1002/ddr.21246. View

18.

Sanyal S, Marckmann P, Scherer S, Abraham J . Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis--an autopsy-based review. Nephrol Dial Transplant. 2011; 26(11):3616-26. DOI: 10.1093/ndt/gfr085. View

19.

Murata N, Gonzalez-Cuyar L, Murata K, Fligner C, Dills R, Hippe D . Macrocyclic and Other Non-Group 1 Gadolinium Contrast Agents Deposit Low Levels of Gadolinium in Brain and Bone Tissue: Preliminary Results From 9 Patients With Normal Renal Function. Invest Radiol. 2016; 51(7):447-53. DOI: 10.1097/RLI.0000000000000252. View

20.

An D, Villalobos J, Morales-Rivera J, Rosen C, Bjornstad K, Gauny S . (238)Pu elimination profiles after delayed treatment with 3,4,3LI(1,2HOPO) in female and male Swiss-Webster mice. Int J Radiat Biol. 2014; 90(11):1055-61. DOI: 10.3109/09553002.2014.925150. View